Jonathan Aguiar

Jan 6, 2025 | nature.com | Eric V. Li |Sai Kumar |Jonathan Aguiar |Clayton Neill |Edward Schaeffer |Ashley Ross

AbstractTraditional nomograms can inform the presence of extraprostatic extension (EPE) but not laterality, which remains important for surgical planning, and have not fully incorporated multiparametric MRI data. We evaluated predictors of side-specific EPE on surgical pathology including MRI characteristics and developed side-specific EPE risk calculators.

Aug 5, 2024 | bjui-journals.onlinelibrary.wiley.com | Eric V. Li |Sai Kumar |Jonathan Aguiar |Mohammad R. Siddiqui

1 INTRODUCTION Pre-biopsy multiparametric prostate magnetic resonance imaging (mpMRI) increases detection of clinically significant prostate cancer (csPCa, defined as ISUP Grade Group ≥2), while avoiding unnecessary biopsies.1, 2 However, with an estimated 299 010 new cases of prostate cancer in the United States in 2024, there is increasing demand for diagnostic prostate MRI, which requires significant financial resources, availability of scanners, and qualified readers.3, 4 The average cost...

Jun 9, 2024 | nature.com | Eric Li |Mohammad R. Siddiqui |Jonathan Aguiar |Sai Kumar |Edward Schaeffer

AbstractMultiparametric prostate MRI (mpMRI) is being increasingly adopted for work-up of prostate cancer. For patients selected to omit biopsy, we identified factors associated with repeat MRI, eventual prostate biopsy, and subsequent detection of clinically significant prostate cancer (csPCa, Grade Group ≥2).

Jun 2, 2024 | nature.com | Jonathan Aguiar

AbstractWe sought to assess erectile dysfunction (ED) medication use among males aged 18–40. Between June and July 2023, a cross-sectional survey on Qualtrics (Provo, UT) was disseminated via Research Match. Among 210 respondents, ED prevalence was 57.1% with 39.0% reporting prior ED medication use.

Mar 7, 2024 | onlinelibrary.wiley.com | Richard Bennett |Eric Li |Austin Ho |Jonathan Aguiar

1 INTRODUCTION Prostate-specific membrane antigen (PSMA) based imaging with positron emission tomography (PET) agents has emerged as a superior method of imaging for initial staging for newly diagnosed prostate cancer (PCa) and for evaluation of biochemical recurrence (BCR).1-3 PSMA scans were first approved by the Food and Drug Administration (FDA) for use in December 2020.